Anavex Life Sciences has announced promising results from their phase 2b/3 trial investigating
blarcamesine, an investigational treatment for early-stage Alzheimer’s disease.
The study showed significant reductions in amyloid-ß biomarkers and a notable
slowing of brain atrophy among treated patients.
The trial, which enrolled 508 participants across five countries, was a multicenter, randomized,
double-blind, placebo-controlled study. Participants were administered either
blarcamesine or a placebo daily for 48 weeks. The primary endpoints focused on cognitive
and functional efficacy, measured through standardized scales such as the
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and the Alzheimer’s
Disease Cooperative Study-Activities of Daily Living (ADCS-ADL).
According to Anavex Life Sciences, blarcamesine-treated patients exhibited a significant
increase in the plasma Aβ42/40 ratio, underscoring the drug’s strong
antiamyloid effect. MRI scans also revealed substantial reductions in brain
volume loss, particularly in the whole brain, when compared to the placebo
group. These findings suggest that blarcamesine could play a critical role in
slowing neurodegeneration in Alzheimer’s patients.
Marwan Noel Sabbagh, MD, emphasized the importance of these findings, stating, “There
is hope that new therapies for Alzheimer’s that target the disease beyond
amyloid may slow progression for many people with the earliest forms of the
disease.” The small, oral nature of blarcamesine, combined with its
excellent safety profile, makes it a particularly appealing option for patients.
The study also reported that the most common treatment-emergent adverse event was dizziness,
which was generally mild to moderate in severity.
Christopher U. Missling, PhD, CEO of Anavex,
expressed gratitude to the study participants and highlighted the significance of the
data. “We look forward to advancing blarcamesine as a potential new,
convenient, orally available treatment option for Alzheimer’s disease,” he stated.
These results mark an important step forward in the quest to find effective treatments for
Alzheimer’s, offering hope to millions affected by this debilitating disease. See
related link for more information.
Find more information about Anavex on https://www.cnbc.com/quotes/AVXL